Sydney · Oceania desk
Australia's trial infrastructure is a capital-efficiency advantage.
Fast ethics approvals, credible data and R&D incentives let Australian and New Zealand companies generate first-in-human evidence at a fraction of US cost. We fund teams that convert that into global assets.
Focus
Clinical evidence · Devices
Cheque
US$10M+
Markets
AU · NZ
Time zone
AEST/AEDT
What we fund in Oceania
Therapeutics and devices using Australian first-in-human data as the bridge to US or European registration.
Digital health with hospital-network contracts and measured clinical outcomes rather than engagement metrics.
Getting to global scale
Most Australasian companies stall at commercialisation, not science. We plan the offshore manufacturing, regulatory and commercial sequence before the round closes.
Frequently asked questions
- Do you invest in New Zealand companies?
- Yes. The Oceania desk covers both Australia and New Zealand.
- Is Australian R&D tax incentive treated as runway?
- We model it explicitly but never rely on it to justify a financing plan.
- What stage do you enter?
- Series A and Series B, from US$10 million, post product-readiness.